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Abstract  34 
Category formation, grouping and read across methods are broadly applicable in toxicological 35 
assessments and may be used to fill data gaps for chemical safety assessment and regulatory 36 
decisions. In order to facilitate a transparent and systematic approach to aid regulatory  37 
acceptance, a strategy to evaluate chemical category membership, to support the use of read-38 
across predictions that may be used to fill data gaps for regulatory decisions is proposed. There 39 
are two major aspects of any read-across exercise, namely assessing similarity and uncertainty. 40 
While there can be an over-arching rationale for grouping organic substances based on molecular 41 
structure and chemical properties, these similarities alone are generally not sufficient to justify a 42 
read-across prediction. Further scientific justification is normally required to justify the chemical 43 
grouping, typically including considerations of bioavailability, metabolism and biological/ 44 
mechanistic plausibility. Sources of uncertainty include a variety of elements which are typically 45 
divided into two main issues: the uncertainty associated firstly with the similarity justification 46 
and secondly the completeness of the read-across argument. This article focuses on chronic 47 
toxicity, whilst acknowledging the approaches are applicable to all endpoints. Templates, 48 
developed from work to prepare for the application of new toxicological data to read-across 49 
assessment, are presented. These templates act as proposals to assist in assessing similarity in the 50 
context of chemistry, toxicokinetics and toxicodynamics as well as to guide the systematic 51 
characterisation of uncertainty both in the context of the similarity rationale, the read across data 52 
and overall approach and conclusion. Lastly, a workflow for reporting a read-across prediction is 53 
suggested.  54 
 55 
Keywords: Read-across; Similarity; Uncertainty; Chemical analogue identification; Prediction; 56 
Toxicity; Regulatory acceptance; OECD; REACH 57 
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Highlights 59 
 60 
 A strategy to evaluate chemical category membership is presented 61 
 Templates to assess similarity and characterise uncertainty are developed 62 
 A strategy to apply new toxicological data to strengthen read-across predictions 63 
 A workflow for reporting a read-across prediction is described 64 
 Read-across prediction to aid in regulatory decisions 65 
 66 
  67 
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1. Introduction and Problem Formulation 68 
Legislative requirements for registration and safety assessment of chemicals have demonstrated 69 
the need for a new way of thinking to obtain toxicological information without resorting to 70 
animal testing. The grouping of substances allowing read-across of toxicity is a valuable method 71 
to obtain such information and potentially has a number of regulatory applications. The 72 
underlying philosophy of read-across is that substances which are similar in chemical structure 73 
will have similar properties and thereby, have similar toxicokinetic and toxicodynamic 74 
properties. Therefore, experimentally-derived toxicological  properties from one substance, often 75 
referred to as the source chemical, can be read across to fill the data gap for a second substance, 76 
the target chemical, which has a similar chemical structure and for which a toxicology study may 77 
be lacking.  78 
Despite the fact that read-across has been used for several years, a number of challenges remain. 79 
For instance, when applying read-across to make a prediction of toxicity, a number of questions 80 
arise, for which answers may be difficult to arrive at or to document; including: 81 
1) Can a robust group of chemicals (often referred to as a chemical category) be formed to 82 
include the target chemical? 83 
2) Is the category formed relevant for the toxicology of the endpoint under assessment? 84 
3) Are there appropriate toxicology studies of high enough quality for the source 85 
chemical(s) to allow a meaningful read-across? 86 
4) What is the uncertainty and is it acceptable to use the read across prediction to fill the 87 
data gap for a specific regulatory purpose? 88 
To begin to address these questions a flexible strategy for developing and reporting a read-across 89 
prediction has been created. The strategy focuses on the two main elements of any read-across 90 
estimation, namely assessing (1) the similarity between target(s) and source substance(s) and (2) 91 
the uncertainties in the read-across process and ultimate prediction. While the standards for 92 
accepting a read-across prediction can vary between regulatory agencies, a good basis is the 93 
standard required for filling a REACH registration information requirement (EC, 2006). 94 
Conceptually, this means, for example, that in the context of a safety assessment for a complete 95 
set of results it should be possible to read-across the findings of a 28-/90-day repeated-dose oral 96 
rat toxicity study on the source substance(s) to the target substance(s). As such, the aim of the 97 
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read-across is to provide a prediction(s) that is (more or less) equivalent to the omitted standard 98 
animal study and hence be acceptable for regulatory purposes. 99 
The intent of this document is to establish a strategy which may be used to conduct and 100 
document read-across predictions for data gap filling. As such, it provides guiding principles for 101 
developing read-across predictions for discrete organic compounds. Where possible, emphasis 102 
has been placed on undertaking and describing the read-across prediction in the best manner to 103 
facilitate regulatory acceptance. This document represents, in part, discussions in and progress 104 
made in the European Commission and Cosmetics Europe funded SEURAT-1 Cluster 105 
(www.seurat-1.eu). As such, the primary focus of this document is directed towards read-across 106 
predictions for chronic toxicity, or improving the possibility to read-across from repeat dose 107 
toxicity tests. However, in order to achieve this aim, the document draws upon current expertise 108 
and knowledge from other toxicological endpoints and the information, templates and work 109 
plans contained herein are generally applicable to all read-across scenarios and endpoints.  110 
In order to facilitate regulatory acceptance, a read-across prediction needs to be justified in all 111 
aspects. Briefly, the justification of a read-across prediction needs to be robust, reliable and 112 
easily explicable. Key principles of similarity need to be clearly documented and, where 113 
possible, supported by scientific literature and data. Sources of uncertainty need to be identified 114 
and accommodated; these can typically be divided into two main types: 1) the uncertainty 115 
associated with the justification of similarity between the source and target structures, and 2) the 116 
uncertainty associated with the application of the particular read-across exercise. 117 
Whilst no consensus has been reached by stakeholders and users, there is growing agreement that 118 
when read-across is applied to make predictions to fulfil information requirements, this must be 119 
done on an endpoint-by-endpoint basis, i.e. for the particular toxicology study to be predicted. 120 
This approach to apply to endpoints individually is due, even when there is an over-arching 121 
category hypothesis, to different applicability domains, different source chemicals and/or 122 
different Weights-of-Evidence (WoE) which may apply to making predictions for different 123 
endpoints. Obviously, there will be occasions where one or more endpoints will be closely 124 
related and knowledge may be transferable, thus allowing read-across arguments to build, 125 
partially, on each other. 126 
7 
 
It is generally agreed that the acceptability of a read-across prediction relies on the explanation 127 
of the similarity which forms the basis of the read-across, as well as the description of the type 128 
and degree of uncertainty associated with the particular read-across. Therefore, it is important to 129 
address these two elements in a transparent and consistent manner. The use of templates or work 130 
plans facilitate the elucidation of the transparency and consistency in read-across. Existing 131 
templates or reporting formats for read-across vary in detail, however, it is generally agreed that 132 
they aim to: 133 
1) Describe the rationale for the similarity between the source and target chemical in a 134 
transparent manner. 135 
2) Document the logic and data leading to the read-across prediction so that, if required, it 136 
can subsequently be recreated. 137 
3) Describe the uncertainties in the prediction; specifically separating the uncertainties in 138 
data and definition of similarity from procedural uncertainty. 139 
4) Clarify the roles of any endpoint specific and/or endpoint non-specific factors affecting 140 
the assessment. 141 
 142 
2. Background 143 
Read-across is an alternative method for filling data gaps based on an analogue or chemical 144 
category approach (van Leeuwen et al., 2009). It is the process of assessing a toxic endpoint of 145 
an untested substance (i.e., target chemical) based on the results for the same endpoint for a 146 
tested substance (i.e., source chemical) considered to be “similar” in the context of structure, 147 
properties and/or activities (Dimitrov and Mekenyan, 2010). It is recognised that forming a 148 
chemical category and data gap filling by interpolation within the category, especially for hazard 149 
assessments, is not a new concept (OECD, 2014a). However, greater emphasis has now been 150 
placed on the resultant read-across prediction due to legislative pressure, especially within 151 
Europe, and especially for classification and labelling, and risk assessment. Currently, there is 152 
growing interest in several national Governmental regulatory agencies to establish best practices 153 
for conducting and evaluating read-across within the context of, and to enable, regulatory 154 
decisions. Published exercises and case studies using the OECD QSAR Toolbox (cf. Enoch et 155 
al., 2013) have demonstrated that category-based read-across can be used to establish that a 156 
substance is associated with potentially hazardous properties. However, it is more difficult to 157 
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show that a substance is not potentially hazardous. In order to address this issue, the more recent 158 
literature has identified some of the challenges which need to be taken into account when 159 
preparing a read-across justification (cf. Patlewicz et al., 2013a; 2014); specifically, case studies 160 
have described the process to create a read-across prediction increasing the likelihood of 161 
regulatory acceptance (cf. Ball et al., 2014). 162 
Much guidance on grouping of chemicals and read-across is already available (ECETOC, 2012; 163 
ECHA, 2009, 2011; OECD, 2007, 2011, 2014a) and the key strategic documents have been 164 
summarised in Table 1.4 of Cronin (2013a). This is a fast moving field and the formation of 165 
chemical categories, or the grouping of molecules, especially to allow for the filling of data gaps 166 
by read-across, has advanced markedly since the start of the 21st Century. Background 167 
information on the processes of grouping and read-across has been detailed by Cronin et al. 168 
(2013). It is clear that interest in chemical category formation, coupled with read-across for 169 
toxicological data gap filling, has grown for a number of reasons (Cronin, 2013a). However, the 170 
primary drivers of this expansion are legislation, which has forced the need for non-test methods 171 
to assess chemical safety and the willingness of regulatory bodies, although it is cautious, to 172 
accept read-across-based submissions in lieu of test results. While there are various advantages 173 
and disadvantages to using the category-based read-across approach in toxicology (Patlewicz et 174 
al., 2013a, 2013b; Cronin, 2013a), the advantages appear to out-weight the disadvantages. As 175 
additional case studies demonstrating the utility and practical application of read-across become 176 
available, the advantages will become more prominent and the challenges more readily 177 
addressed.  178 
All applications of read-across are context dependent and any read-across adaptation (i.e., the 179 
formal process by which a prediction is used for regulatory purposes) is likely to be performed 180 
with limited sets of experimental data. Thus, successful adaptations of a read-across are 181 
contingent not only on the appropriate selection of the characteristics, measures of similarity and 182 
assessment of the uncertainties associated with the prediction, but also on the quality and 183 
quantity of the information and data used in the exercise. 184 
Within the applicability domain of a chemical category, read-across can be performed to fill data 185 
gaps with a number of approaches which can be summarised into the following four techniques: 186 
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1) one-to-one read-across (i.e., one source substance used to make a prediction for a single 187 
target chemical), 188 
2)  many-to-one read-across (i.e., two or more source substances used to make a prediction 189 
for a single target chemical), 190 
3) one-to-many read-across (i.e., one source substance used to make a prediction for two or 191 
more target chemicals), or 192 
4) many-to-many read-across (i.e., two or more source substances used to make predictions 193 
for two or more target chemicals). 194 
Techniques 3 and 4 may be considered as being multiple simultaneous applications of techniques 195 
1 and 2, respectively. Given limited data availability, the “one-to-one”, or analogue approach, is 196 
often the only viable option. Ideally, however, the “many-to-one” or category approach is 197 
preferred as it inherently possesses a greater WoE in that each analogue in the category supports 198 
the others. 199 
With reference to the above applications (one/many-to-one/many), it is recognised that read-200 
across for toxicity prediction can be qualitative or quantitative in design. A qualitative read-201 
across provides a “yes/no” prediction for an effect; quantitative read-across provides quantitative 202 
(i.e., potency) values for an endpoint. When conducting a quantitative read-across exercise, the 203 
OECD suggests that there are four main approaches to making the prediction (OECD 2014a):  204 
1. reading across from the endpoint value of a similar chemical (e.g., the closest source 205 
chemical);  206 
2. applying a mathematical scale to the trend in available experimental results from two or 207 
more chemicals similar to the target chemical (e.g., trend analysis or structure-activity 208 
relationships); 209 
3. processing the endpoint values from two or more source chemicals (e.g., by averaging, by 210 
taking the most representative value), or; 211 
4. when sufficient data allow, taking the most conservative value among the source 212 
chemicals within the whole category. 213 
Establishing similarity on an apical endpoint-specific basis is essential to successful category 214 
formation and read-across (ECETOC, 2012). Chemical similarity can be considered in a number 215 
of ways (Enoch and Roberts, 2013). Critical to the justification of analogue(s) selection for read-216 
across is the explanation of seminal criteria of chemical similarity on which the selection is 217 
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based. The definition of these criteria is an on-going issue since chemical similarity may be 218 
assessed in many ways and, even when assessed objectively, not all measures of chemical 219 
similarity are of equal importance and there is no simple similarity scale. In the extreme, each 220 
chemical can be considered as its own category; however this is obviously not practical for 221 
predictive purposes. In addition, it is accepted that simple measures of chemical similarity (e.g., 222 
being a member of a simple organic chemical class, having the same carbon skeleton or same 223 
function group) are often not practical for making predictions. Thus, as noted by Enoch and 224 
Roberts (2013), in order for any read-across prediction to gain acceptance, it is essential to 225 
explain the basis for similarity between the target chemical(s) and source chemical(s) in a robust 226 
and reliable manner. 227 
After a read-across exercise is carried out, an assessment is undertaken of whether the case 228 
supporting the read-across is sufficient for the prediction to be acceptable. This acceptance is 229 
often stated in the form of confidence or certainty. While the acceptance of read-across 230 
predictions is often made according to a standard procedure (e.g., an assessment framework), 231 
ultimately the evaluator(s) must be convinced of the scientific credibility of the premise of the 232 
read-across and the supporting data provided. Therefore, assuming the rationale for similarity is 233 
accepted (i.e., the category is robust and membership is assured), final acceptance of the read 234 
across prediction is contingent on reducing uncertainty. While uncertainty is related to the 235 
quality and quantity of the read across endpoint data (Cronin, 2013b; Péry et al., 2013; 236 
Blackburn and Stuard, 2014), there are a number of other factors that influence uncertainty. 237 
 238 
2.1 Regulatory Context and International Efforts to Address Read-Across Predictions  239 
 240 
In order to understand the context of the development of read-across, it is important to consider 241 
how it has been developed and shaped as a data gap filling approach with regard to legislative 242 
and regulatory pressure. Globally, a multiplicity of regulatory agencies is applying read-across in 243 
their decision making processes. While a number of these agencies are currently focusing efforts 244 
on how to best standardise the development and evaluation of read-across predictions, the 245 
European CHemical Agency (ECHA), especially through the provisions in Registration, 246 
Evaluation, Authorisation and Restriction of Chemicals (REACH) is among the better known. 247 
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Specifically, REACH allows for adaptations to the standard information requirements by means 248 
of read-across of a study conducted on a source substance to a target substance (cf. Annex XI in 249 
EC, 2006). 250 
The standard ECHA advice to registrants on making and documenting a good-quality read-251 
across/category (ECHA, 2013a; 2013b) refers to the importance of making a clear read-across 252 
hypothesis and justification. Non-testing approaches to data gap filling have also garnered much 253 
attention at the Organisation for Economic Co-operation and Development (OECD) and among 254 
its member countries. Specifically, among the OECD member countries, read-across is used as 255 
an alternative method for hazard identification and characterisation in risk assessments; read-256 
across is especially useful when based on grouping approaches, because not every chemical 257 
needs to be tested (OECD, 2014c). 258 
Since the regulatory use of read-across relies on the scientific validity and the robustness of the 259 
justification substantiating the prediction for a given endpoint(s), there are a number of issues 260 
associated with read-across which may benefit from international discussion on a broader scale. 261 
Experiences reported by the OECD members indicate that there is still a lack of agreement on 262 
what “chemical similarity” is. Specifically, the OECD has noted the challenge posed by the facts 263 
that: 1) a chemical category is defined by a variety of factors, 2) there are no simple similarity 264 
scale(s), and 3) similarity can also depend on the endpoint under consideration (OECD, 2014c).  265 
Work at OECD has revealed that similarity hypothesis can be based on a variety of aspects, and 266 
definitions, of, chemistry. OECD has also concluded that these methods of assessing similarity 267 
are not equal in obtaining a robust chemical category for toxicological read-across. Read-across 268 
based on mechanistic similarity (e.g., common chemical interaction with a receptor) is generally 269 
considered a better similarity hypothesis than an informatics based similarity metric. However, 270 
knowledge of the mode or mechanism of action is not always available, especially for the more 271 
complex endpoints such as repeated dose toxicity. Moreover, information on transformation 272 
products and the rate of formation of these products is likely to be the key factor in accepting 273 
read-across predictions. Thus, information derived from experimental studies, as well as 274 
toxicokinetic information and ADME information, will contribute to justify the prediction. 275 
The current view of OECD (OECD, 2014c) is that more experience is needed on how the 276 
confidence in the prediction could be enhanced by providing more mechanistic transparency, 277 
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using experimental data from structural analogues, using data that are supplemented by 278 
toxicokinetic and ADME information, and using data that are supplemented by relevant in vitro 279 
and in chemico endpoints (i.e., incorporation of more information to increase the WoE). More 280 
specifically, the OECD has emphasised the following as being crucial to the successful 281 
application of read-across: 1) the process of how to document the justification for a read-across, 282 
2) consideration of how to perform read-across for more complex endpoints (e.g., repeated dose 283 
toxicity), 3) development of approaches and agreement of use of quantitative read-across for 284 
hazard characterisation, 4) methods to better take mechanistic considerations into account in 285 
grouping chemicals, and 5) approaches to derive WoE conclusions based on results from 286 
alternative methods or supplementary information. 287 
While the details may vary, it is obvious from all the regulatory requirements and guidance that 288 
any general strategy to assess the justification for a read-across prediction must examine whether 289 
or not the key principles of similarity are clearly documented and whether the interpretation is 290 
supported by scientific justification based on argumentation, literature and data. Development of 291 
the similarity rationale, whether for an analogue or a chemical category, must be performed on a 292 
case-by-case basis. This case-by-case basis is likely to be influenced by the availability of 293 
suitable data to populate the category and be specific to the regulatory endpoint being evaluated 294 
(i.e., complex endpoints may intrinsically require greater confidence in the similarity argument 295 
and data). Read-across arguments often adopt a multifaceted approach that combines several 296 
similarities into a single rationale. This approach, where similarity between the source and target 297 
chemicals is demonstrated across multiple parameters, is designed to reduce uncertainty 298 
associated with the read-across prediction. 299 
Acceptance of a read-across prediction is often couched in the evaluator’s sense of confidence 300 
or, more accurately, certainty in the prediction. In the end, high confidence (i.e., low concern 301 
about potential error in the prediction) is assigned to a read-across when there is strong proof the 302 
prediction is valid (i.e., low uncertainty). This confidence is often gained by identifying and 303 
addressing the sources of uncertainty. 304 
Finally, it is recognised that the OECD is currently conducting further work on the hazard 305 
assessment of chemicals. Through the Task Force on Hazard Assessment, the OECD is 306 
developing Integrated Approaches to Testing and Assessment (IATA). Included in this effort is 307 
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the examination of grouping approaches and the exchange of experiences among the member 308 
countries on new hazard assessment methodologies. A goal of this work is to achieve a 309 
harmonised approach to the implementation of IATA, so as to ensure consistency in how 310 
information is used in regulatory decision-making and to foster mutual acceptance of 311 
assessments (OECD 2014c). This knowledge and experience will add to the understanding of the 312 
process of category formation and use of read-across. 313 
 314 
3. Defining the Criteria for Category Membership: Establishing Similarity 315 
To meet regulatory needs, the read-across hypothesis, or justification for the read-across within a 316 
defined chemical category of discrete organic substances, must include a clear definition of the 317 
criteria (i.e., chemical similarity) for membership of the category (i.e., a clear definition of the 318 
applicability domain). Within the REACH regulation, read-across is founded on the principle o 319 
of “structural similarity” combined with a scientific justification. Therefore, within the OECD 320 
guidance for read-across, the basis for assessing similarity is typically elaborated with the 321 
possibility of other considerations (e.g., bioavailability, toxicokinetics/metabolism) to assess 322 
analogue similarity (OECD, 2014a). Moreover, a useful tool that might be employed for 323 
demonstrating commonality in toxic behaviour is through an adverse outcome pathway concept; 324 
this implies assessing similarity “via molecular initiating events”, “key intermediate events” and 325 
“other relative in vitro” information and data (OECD, 2013; 2014b). Clearly, the basis for 326 
establishing the applicability domain of a category will depend both on the endpoint and 327 
chemical and means of forming a category e.g. a specifically vs. broadly defined fragment. Thus, 328 
the questions “Can a chemical category be formed?” and “Is the category toxicologically 329 
relevant?” are often addressed concurrently. 330 
Building on six case studies using the information within the OECD QSAR Toolbox (Enoch et 331 
al., 2013) and the earlier work of Blackburn et al. (2011) and Wu et al. (2010), it is clear that 332 
chemical category membership can be defined by many factors. Table 1 summarises the factors 333 
leading to category membership being adequately defined and supported into three elements. 334 
  335 
14 
 
TABLE 1 HERE 336 
 337 
While there can be a starting premise or over-arching rationale for grouping organic substances 338 
based on molecular structure and chemical properties, these similarities alone are generally not 339 
sufficient to justify a read-across prediction. Typically, further information is required to justify 340 
the chemical grouping on the basis of considerations such as bioavailability, reactivity, and 341 
metabolism. Similarity in bioavailability is also crucial to confirm where possible. Read-across 342 
should be performed where similar bioavailability can be demonstrated. Currently, without 343 
experimental data, it is difficult to obtain realistic estimates of bioavailability in silico, however 344 
progress is being made in areas such as predicting metabolism and clearance rates which 345 
combined could provide usable descriptors. For read-across predictions for the less complex 346 
endpoints (e.g., acute aquatic toxicity), adding these toxicokinetic similarities is often enough to 347 
justify a read-across prediction. However, for the more complex endpoints (e.g., chronic health 348 
toxicities), additional measures of similarity are necessary for read-across prediction to be 349 
acceptable. 350 
While there is no definitive list of similarities with in a group, eleven similarities which are 351 
proposed that to have an impact on forming the chemical category for a read-across prediction, 352 
are summarised in Table 2. In order to be both transparent and comprehensive, it is suggested to 353 
collect similarity data for as many criteria as possible. Whilst molecular structure similarity is a 354 
highly pragmatic approach to identify potential source analogues, it is not on its own sufficient to 355 
justify read across, and indeed it may not be the most important element. 356 
 357 
TABLE 2 HERE 358 
 359 
Data for molecular structure and physico-chemical properties to support grouping hypotheses 360 
can be easily obtained in silico from software such as the OECD QSAR Toolbox. Using two-361 
dimensional molecular structure, structural data can be organised into groups of atoms 362 
representing rings (e.g., benzene or naphthalene), linkers (i.e., atoms in a direct path connecting 363 
two ring systems), frameworks (i.e., the combination of ring systems and linkers in a molecule), 364 
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and side chains (i.e., non-ring, non-linker atoms) (Bemis and Murcko, 1996). These molecular 365 
scaffolds provide a basis for assessing similarity. Common constituents include substituents 366 
(e.g., the 166 well-characterised, common organic moieties described by Hansch and Leo, 1979) 367 
and structural fragments (e.g., the 645 fragments used in the US EPA’s the Analog Identification 368 
Methodology (AIM)). In addition, physico-chemical and molecular property similarities include 369 
properties which are linked to key factors that affect toxicity (e.g., volatility, solubility, 370 
reactivity, etc.).(http://www.epa.gov/oppt/sf/tools/aim.htm). 371 
Five types of similarity (Items 3-7 in Table 2) are typically considered to meet the similarity 372 
hypotheses for grouping chemicals for read-across based on common toxicokinetics and/or 373 
abiotic transformation; these factors largely focus on metabolism which often has significant 374 
uncertainty associated with it due to the potential difficulty in obtaining experimental or in silico 375 
data. Transformation similarities focus on the likelihood of attaining common or similar 376 
precursors and/or breakdown products, via physical or biological processes. This includes key 377 
abiotic transformations (e.g., hydrolysis, autooxidation) and toxicokinetics (ADME), the same 378 
key metabolic pathway(s) or pathway inhibition, activation to same or similar reactive chemical 379 
species and degradation to the same or similar chemical species. 380 
For read-across based on common biological/toxicological factors, three types of similarity; 381 
toxicophores, mechanistic plausibility and related endpoints, are mostly considered (Table 2), the 382 
most important of which is mechanistic plausibility. The AOP construct, an excellent concept for 383 
adding mechanistic understanding into the read-across, is one of several means of establishing 384 
mechanistic plausibility. In addition, similarity in the biological (preferably in vivo) data, such 385 
that are available will provided additional evidence for category membership,  386 
In the initial phase of developing a read-across, it is advisable to collect information on similarity 387 
and data for as many of the criteria listed in Table 2 as possible. However, it is intuitive that the 388 
most critical measurements of similarity are endpoint- and scenario-dependent and hence will 389 
require expert judgment and application. In amassing information on similarity (for regulatory 390 
applications in particular) it is essential to explain the basis for the similarity between the target 391 
chemical(s) and the source chemical(s) in sufficient detail to be able to judge fit for purpose. 392 
There are a number of potential regulatory purposes for performing, and uses of, a read-across 393 
prediction. The regulatory purposes include: 1) Prioritisation and Screening, 2) Hazard 394 
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Identification (potential), 3) Hazard Characterisation (potency), and 4) Safety Assessment 395 
(potential/potency and exposure). Thus, in assessing the similarity associated with grouping, it is 396 
important to do so in the context of the decision being considered and the scope of the problem. 397 
The “context” and “scope” significantly influence a number of issues including the similarity 398 
rationale(s) required to form the category and identify analogues. 399 
The regulatory purpose of the read-across often determines the type(s) of similarity required. It is 400 
currently accepted (c.f., Cronin et al. (2013), that there are three broad criteria of similarity: 1) 401 
chemistry, 2) transformation, and 3) toxicology. In consideration of Prioritisation and Screening, 402 
hazard identification and safety assessments greater and more detailed information is required on 403 
similarity as described further in Section 4. Therefore, in order to achieve the goal of “fitness for 404 
purpose” (i.e., to be both transparent and comprehensive in the justification of a read-across) it is 405 
advisable to collect data for as many of these similarity criteria listed in Table 3 as possible. To 406 
assist in this process of collecting and assessing information relating to similarity, a template for 407 
assessing similarity of analogues and category members for read-across has been proposed and is 408 
reported in Appendix A.  409 
This proposed template to collect information to establish similarity includes an overall 410 
conclusion regarding the rationale for analogue/category similarity (this is provided as a text box 411 
in the Template in Appendix A). The conclusion is intended to summarise all relevant scientific 412 
information relating to establishing similarity, in order to clearly justify the analogue(s) selected. 413 
The overall rationale for similarity is established by assessing the various criteria for similarity. 414 
This is achieved by answering the following questions relating to chemical, transformational and 415 
toxicological similarity.  416 
 417 
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  419 
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4. Confidence and Uncertainty 420 
There is general agreement that increased uncertainty has a strong negative impact on a read-421 
across prediction and often negates the use of the read-across method. For that reason, 422 
uncertainties need to be identified and appraised (Cronin et al., 2013; Ball et al., 2014; Blackburn 423 
and Stuard, 2014; Patlewicz et al., 2014). However, the concept and definition of uncertainty has 424 
been described as ambiguous; it tends to incorporate a variety of methodologies with the aim of 425 
meeting different goals (Péry, et al., 2013). As a result, a major challenge for the better use of the 426 
read-across approach lies in making the concept of uncertainty more understandable and 427 
transparent. Currently, determining how much uncertainty is acceptable for a read-across 428 
prediction is still largely subjective. It is defined on a case-by-case basis and influenced heavily 429 
by the purpose of the prediction, the endpoint assessed, and whether the read-across predicts the 430 
presence or absence of toxicity. 431 
To date, the most comprehensive method for gauging uncertainty for read-across, especially for 432 
chronic health effects (e.g., repeated dose toxicity), is in the “framework” of Blackburn and 433 
Stuard (2014). This is a prescriptive scheme for addressing the various facets of uncertainty as it 434 
pertains to read-across. Specifically, it is designed to: 1) increase transparency of the read-across 435 
prediction, 2) provide consistency to the exercise, 3) provide a means of examining robustness 436 
and consistency among the key facets of similarity, 4) facilitate review and evaluation of the 437 
read-across exercise, and 5) help identify where additional data may be helpful, especially in 438 
reducing uncertainty. The Blackburn-Stuard framework does not, however, completely remove 439 
subjectivity from the process, as expert judgment is still required to categorise uncertainty. In 440 
addition, the Blackburn-Stuard framework defines four levels of uncertainty (i.e., low, low to 441 
medium, medium and high) and proposes quantitative factors (i.e., 1, 3 and 10, respectively) for 442 
addressing the three lesser levels, with the uppermost level of uncertainty being deemed 443 
unsuitable for the application of the read-across method. The numerical uncertainty factors serve 444 
to build conservatism into the potency prediction and weigh the unknown associated with the 445 
prediction. While the framework is new and largely untested, the scheme appears to be good for 446 
repeated dose toxicity endpoints where assessment factors can be applied to NOAELs. More 447 
quantitative approaches for assessing uncertainty are provided below.  448 
Sources of uncertainty include a variety of elements which are typically divided into two main 449 
issues. The first issue is uncertainty associated with similarity justification, and the second is 450 
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associated with the overall approach and conclusion. With regard to the uncertainty associated 451 
with similarity justification, this implies that there are inherent uncertainties associated with the 452 
presumption that the results of the in vivo study/ies on the source chemical(s) apply (i.e., can be 453 
read across) to the target analogue(s). The justification for this presumption is based on two 454 
interrelated rationales: 1) that the target and source materials are sufficiently similar to be 455 
toxicologically relevant, and 2) that supporting arguments are provided to justify that the 456 
differences in chemical structure do not affect the properties relevant to the specific endpoint 457 
under consideration. 458 
The assessment of uncertainty associated with similarity justification includes consideration of 459 
the information supporting the scientific arguments for similarity and data associated with the 460 
chemical, toxicokinetic and toxicodynamic similarity resulting in the toxicity being read across. 461 
As stated previously, chemical-based toxicological similarity may be established by responding 462 
to the questions posed in Table 3 which may be achieved by following the template presented in 463 
Appendix A. Uncertainty associated with the answers to the questions in Table 3 is assessed in a 464 
uniform manner and a WoE, indicating consistency in quality and quantification of the data for 465 
each feature, assigned (Appendix B, Table B.1) 466 
Among the uncertainties are those brought about by deficiencies in the underlying knowledge 467 
and data associated with assessing the essential areas of similarity. Chemical similarity, in itself, 468 
may never be enough to justify fully a read-across prediction. While molecular structure and 469 
physico-chemical properties play a role in assessing similarity, depending on the toxicological 470 
endpoint under consideration, these factors by themselves may not be enough. For example, for 471 
chronic health endpoints, two structurally similar chemicals may have significant differences in 472 
toxicity. In these cases, toxicokinetic and/or biological similarity may be more important. When 473 
such information is lacking, specific studies may be necessary to confirm the premise of the 474 
similarity justification or, as a minimum, reduce the uncertainty in the similarity to an acceptable 475 
level for the intended purpose. Such a confirmation of biological similarity may be obtained 476 
from the comparison of toxicological profiles derived from, for instance, non-animal tests. 477 
However, in such cases, it may be complex and require expert judgement to select the 478 
appropriate in chemico method, in vitro assay or possibly an in silico tool to provide the critical 479 
information needed to strengthen a similarity rationale. 480 
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The second issue of uncertainty is associated with the completeness of the read-across argument. 481 
The molecular nature (e.g., complexity of molecular structure) of the target chemical(s), the 482 
nature and complexity of the apical endpoint to be read across, the premise or hypothesis of the 483 
read-across, the purpose of the prediction as well as the quality and robustness of the data all can 484 
have an impact on uncertainty, its definition and acceptability for read-across (Table 5).  485 
The molecular nature (e.g., complexity of structure) of the target chemical(s) (2nd bullet in Table 486 
5) implies that target chemicals with simple molecular structures (e.g., a hydrocarbon scaffold 487 
and one functional group) impart less uncertainty than a more complex molecular structure (e.g., 488 
a heteroatom scaffold with multiple structural groups). 489 
In terms of chemistry, the more narrowly defined the applicability domain of the grouping, the 490 
greater the confidence can be placed in the group membership and hence, the less the 491 
uncertainty. For example, low uncertainty is associated with all category members having the 492 
same functional groups and appropriately similar key physico-chemical and molecular properties 493 
(e.g., aliphatic aldehydes with C2 to C5). 494 
Relating to the problem and premise of read-across (1st bullet in Table 5), it is intuitive that 495 
reading across from many-to-one provides lower uncertainty than reading across from one-to-496 
one, assuming that the standard of the available in vivo data of the source substances, and the 497 
trends within them, are comparable. Further uncertainty may be associated with the apical 498 
endpoint itself, which is to be read across. For some endpoints, chemical mechanism and/or 499 
biological modes-of-action are well-established (e.g., mutagenicity). However, for other 500 
endpoints (e.g., repeated dose toxicity), the lack of a mechanistic understanding tends to 501 
introduce greater uncertainty into the similarity rationale. Mechanistic uncertainty is best 502 
assessed within the context of an AOP. It is recognised that knowledge of an AOP evolves and, 503 
as such, AOP development represents a continuum from less-to-more complete with increasing 504 
quality, quantification and strength of key events (KEs) and key event relationships (KERs) 505 
(Tollefsen et al., 2014). Confidence in using an AOP is typically informed by: 1) support for the 506 
biological plausibility of KEs, KERs in relationship to the in vivo apical outcome under 507 
consideration, 2) support for the essentiality of the MIE and other KEs, and 3) empirical data 508 
quantifying the KEs and support for the KERs.  509 
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As an example, typically, there is more uncertainty with a developmental toxicity endpoint 510 
versus a genotoxic endpoint. A chemical which can cause DNA or chromosomal damage is 511 
deemed a genotoxin. As such, many in vitro and in vivo tests for genotoxicity have been 512 
developed with a range of endpoints that either detect DNA or protein damage or a genotoxicity-513 
related biological consequence; causal linkage between the interaction of a chemical with 514 
biomolecules at the molecular level and subsequent in vitro and in vivo genotoxic effects are 515 
well-established (Petkov et al., 2015). The net result is that there are practical methods of 516 
integrating in silico and in vitro results to reduce uncertainty in predicting genotoxicity outcomes 517 
of untested chemicals. In contrast, there are a variety of interactions of a chemical with 518 
biomolecules which can subsequently lead to adverse developmental effects (Wu et al., 2013). 519 
Many of the interactions that underpin developmental toxicity may not be defined in detail and it 520 
may not be possible to obtain data for Key Events in the AOP, even for well defined events. 521 
Thus, the read-across of developmental toxicity is implicitly associated with greater uncertainty 522 
than for well described and “modelled” endpoints. Linked to this concept is the realisation that 523 
there are several sources of uncertainty in supporting biological justification. These sources, 524 
which are relevant for all systemic endpoints, include: 1) incomplete knowledge of the biological 525 
mechanism(s) resulting in toxicity, 2) relevance and completeness of the supporting evidence in 526 
the form of scientific information and/or test data, and 3) problems with the test data (e.g., 527 
variability in results, lack of understanding what the results mean, etc.). Once the weaknesses or 528 
data insufficiencies in the justification are documented, new method evidence can be added to 529 
address the shortcomings and reduce the uncertainty. 530 
The read across endpoint(s) is another focal point of the exercise. The type of endpoint read-531 
across effects uncertainty and as more complex endpoints are addressed, there will be a greater 532 
WoE required to justify category membership. Simpler endpoints (e.g., acute toxicity) may be 533 
readily addressed with fewer lines of evidence supporting the biological justification; often, a 534 
single toxicity profiler or small group of in vitro tests are sufficient to establish the chemical 535 
category or analogue and support the read-across. In contrast, for more complex endpoints, such 536 
as chronic health effects which are traditionally assessed by higher level in vivo tests (e.g., 28-537 
day repeated dose testing), establishing the category is more difficult. In the case of complex 538 
endpoints, analogues are often identified by WoE, looking at consistency in empirical and/or 539 
model data across a number of mechanistically relevant endpoints. For example, read across for 540 
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skin sensitisation may require a WoE call after gauging uncertainty in skin metabolism or abiotic 541 
oxidation, as well as chemical reactivity leading to protein binding and dendritic cell activation. 542 
In contrast, reading across for oral in vivo mutagenicity may require gauging uncertainty in 543 
microbial transformation in the gut, metabolic activation in the liver and chemical reactivity 544 
leading to DNA-binding and would probably require a lower overall WoE than for chronic 545 
toxicity. The depth and breathe of the information and empirical data for these different activities 546 
affect the overall level of uncertainty allowed, while still accepting the prediction via the WoE. 547 
The problem and premise of the read-across significantly influence both the similarity rationale 548 
required to form an appropriate chemical category and the empirical data of sufficient quality 549 
required for the source chemical. 550 
 551 
TABLE 4 HERE  552 
 553 
Thus, taking the scenarios summarised in Table 4, in Scenario 1 toxicokinetics are less critical to 554 
establishing similarity and establishing a source chemical as being of high quality than in 555 
Scenario 2. In fact, the absence of toxicokinetic data for Scenario 2 may mean the uncertainty is 556 
too great as to prevent the use of read-across without further testing. In addition, a read-across 557 
prediction of the absence of an adverse effect carries with it a greater perception of uncertainty. 558 
In this case it is not possible to demonstrate with absolute certainty that a target chemical does 559 
not elicit a particular in vivo adverse effect (Scenario 3), however it may be possible to reduce 560 
uncertainty by demonstrating the absence of sub-cellular and cellular responses (i.e., negative 561 
results from molecular screening and toxicogenomics). In Scenario 4, one of the key questions to 562 
be addressed is whether sub-categorisation is required to reduce the uncertainty associated with 563 
the applicability domain of the read-across. The purpose of the prediction also impacts the 564 
degree of uncertainty that is acceptable. 565 
While most previous publications discussing read-across have focused on its application in safety 566 
assessment, read-across may be used to fill other needs. As noted earlier, there are four 567 
regulatory uses for using read-across predictions that apply three basic types of similarity. The 568 
purpose of the prediction may determine the types of similarity required that can be used, and 569 
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thus influences uncertainty. Prioritisation and screening may be amenable to prediction based 570 
only on information from analogue chemistry. Hazard identification may require information on 571 
both chemistry and toxicology similarity. However, hazard quantification for risk assessment 572 
will normally needs dosing route and transformation similarity to assess exposure and 573 
toxicological similarity; in addition there may be an assessment of  mechanistic plausibility, 574 
perhaps based on an AOP.  575 
The uncertainty that is associated with the in vivo toxicology study/ies on the source chemical(s) 576 
is always case-specific. Assessments should focus on any deficiencies in the quality of the 577 
toxicology data to be read across, especially as compared to what is expected from current 578 
standard test methods. Questions 3-4 in Table 5 are designed to address uncertainty associated 579 
with the in vivo data being read across (a number of methods are available to ascertain toxicity 580 
data quality, with the reader being referred to (Klimisch et al., 1997; Przybylak et al., 2012; 581 
Steinmetz et al., 2014; Yang et al., 2013) for further information). Conversely, the final three 582 
questions in Table 5 are designed to address uncertainty associated with in chemico, in vitro or in 583 
silico data used to strengthen the similarity rationale. Lower uncertainty may also be assigned 584 
when empirical and in silico measurements of chemical properties are in good agreement. 585 
The qualification of transformation impacts uncertainty, especially with respect to metabolism 586 
for the category members without empirical data. For example, low uncertainty is associated 587 
when all category members have similar ADME properties. Although there is uncertainty 588 
associated with predictions from in silico tools, the uncertainty is considered lower when 589 
empirical studies (in vivo and/or in vitro) and model predictions indicate similar metabolism. In 590 
addition, information on the purity of compounds being considered and read across must be 591 
included as this may affect the certainty. 592 
 593 
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 595 
The uncertainty associated with a read-across prediction is impacted by several additional 596 
features, especially those associated with the completeness and application of the read-across 597 
procedure; this knowledge is typically summarised in an overall assessment of the WoE. In 598 
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assessing the uncertainties associated with a particular read-across, it is important to put in 599 
context both the problem and premise of the read-across. A statement of the problem includes 600 
noting the target chemical(s), the apical endpoint to be read across and the purpose of the 601 
prediction. Stating the target chemical(s) is critical, as it is one of the focal points of the exercise. 602 
Scaling uncertainty is a formidable challenge (Péry, et al., 2013; Blackburn and Stuard, 2014). 603 
While there is much agreement on what the essential issues of the read-across are that need to be 604 
considered in assessing uncertainty, there is less agreement on what approach to use. At least 605 
three approaches could be applied: 1) a sliding scale, which can be tailored to the particulars of 606 
the read-across (i.e., problem and premise), 2) a weighted scale, where some issues or their 607 
related narrative and/or question(s) used to frame the issue are weighed more than others, and 3) 608 
pre-defined divisions, where all issues or their related narrative and/or questions are assigned a 609 
value in a parallel fashion. The first two approaches, while interesting academic exercises are 610 
likely to be too complex to be practical. Thus, the third approach, the pre-defined divisions 611 
approach, is the most likely to be used. Within the latter approach, there is variability in the 612 
number of divisions employed. A dichotomous decision scheme (i.e., accept or reject) does not 613 
provide any refinement to the assessment; whereas, a multi-divisional scheme will provide the 614 
opportunity to add confidence statements into the assessment (e.g., low. medium, high). A five-615 
division scheme (or larger) may offer too much subjectivity in assigning the division. The four-616 
division scheme (i.e., low, low to moderate, moderate and high) described by Blackburn and 617 
Stuard (2014), appears to provide a balance between a high number of possible divisions and 618 
reduced subjectivity in assigning the final division. The Blackburn and Stuard scheme provides 619 
three divisions of uncertainty where the prediction may potentially be usable; with the fourth 620 
division indicating high uncertainty such that the read-across method is unfit for data gap filling. 621 
The “characteristics by uncertainty” for the low and low-to-medium divisions are much the 622 
same, with latter divisions including a WoE evaluation. Initially, read-across case studies are 623 
likely to involve extremely-well studied categories and analogues which fit the low uncertainty 624 
division of Blackburn and Stuard (2014). However, in the future, the more common read-across 625 
predictions, especially for chronic health effects, should include a WoE evaluation. 626 
Uncertainty factors are used to build conservatism into assessments and address the unknown 627 
associated with a prediction. Converting uncertainty “divisions” (as reported by Blackburn and 628 
Stuard, 2014) to numerical uncertainty factors provides another challenge. Excluding the “high” 629 
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uncertainty division, since reaching this level of uncertainty precludes using read-across to fill a 630 
data gap, one is left with assigning three uncertainty factors. There are a variety of numerical 631 
scales (e.g., 1-2-3; 1-10-100; 1-3-10; 1-5-10) which may be employed to cover a three-division 632 
scheme. A 1-2-3 method provides insufficient differentiation of uncertainty; conversely, a 1-10-633 
100 provides too much differentiation. The 1-3-10 method proposed by Blackburn and Stuard 634 
(2014) remains a pragmatic and usable solution and is recommended for use at this time. 635 
However, as case studies become available, especially for those where the read-across is less 636 
conclusive (i.e., low-moderate or moderate), further evidence may become available to evaluate 637 
this proposal more fully, for example to explore the difference in employing a 1-3-10 versus a 1-638 
5-10 quantification method. 639 
 640 
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 642 
Table 6 summarises the main similarities that need to be considered when assessing a read-across 643 
justification, along with how they may be related to specific levels of uncertainty. Table 6 also 644 
demonstrates the value of including novel toxicological data to read-across predictions with the 645 
aim of decreasing uncertainty. It is likely that uncertainty associated with core structure and 646 
functional groups, as well as physicochemical and molecular properties, can be assessed 647 
relatively easily. However, because of information gaps, it is likely that uncertainty associated 648 
with comparable toxicokinetics and similar mechanistic and toxicological properties, especially 649 
for chronic health endpoints, will be more difficult to assess. 650 
Consideration of all the evidence (e.g., the uncertainties defined in queries such as Table 5, 651 
supporting data and information etc.)  provides the basis for the WoE. It is not only the quantity 652 
and quality of evidence that affects WoE but also consistency across all aspects of the 653 
information/data used to support the similarity rational and prediction. For example, whilst 654 
relative uncertainties may be the same, it is intuitive that reading across from many-to-one with 655 
consistent phenotypic expressions of toxicity provides a greater WoE than reading across from 656 
many-to-one with varied phenotypic expressions of toxicity. This has particular implications in 657 
Scenario 4 of Table 4 where multiple mechanisms of action may be present. In terms of 658 
chemistry, a greater WoE is assigned when empirical and in silico estimates of chemical 659 
25 
 
properties are in good agreement with measured values. In a similar fashion, the WoE is 660 
considered higher when empirical studies of metabolism (in vivo and/or in vitro) and model 661 
predictions indicate similar metabolites. Mechanistic plausibility can be more difficult to 662 
consider, however consistent empirical data for the target chemical and, where possible, the 663 
target chemical and the source chemical(s) for the MIE and/or other KEs strengthens the WoE. 664 
Similar arguments can be made for other relevant, in vivo, in vitro and ex vivo endpoints. 665 
Concordance across other endpoints (where data exist) is also a relevant consideration. For 666 
example, acute oral LD50 data are not part of the mechanistic understanding for oral repeated 667 
dose toxicity but having a consistent trend in empirical data among category members may 668 
improve the overall WoE. 669 
A template has been provided to identify and assess uncertainty in a comprehensive and 670 
transparent manner. The template is available in Appendix B and it is recommended for use to 671 
assess the uncertainty associated with each similarity parameter used in the read-across and to 672 
summarise these finding in a statement of uncertainty. The first aim of the template was to 673 
identify the factors of the read-across that contribute to uncertainty in the prediction. These 674 
include uncertainty associated with the scientific justification of the similarity that defines the 675 
applicability domain of the category or source and target analogue, as well as the uncertainty 676 
associated with the read-across. The second aim was to define levels of uncertainty and propose 677 
quantitative factors for addressing each level. 678 
Table B.1 of the template in Appendix B lists and describes the key issues of chemical, 679 
transformation/toxicokinetic and toxicological similarity proposed to assess data uncertainty and 680 
WoE (see tables A.1-A.8). The comment column is not intended to be all inclusive but rather 681 
give an indication of the type information that may be included. Table B.2 of the template in 682 
Appendix B provides the capability to assess the issues raised in Table 5 above. The aim was to 683 
assess the non-similarity-based uncertainty associated with the read-across. The first item in 684 
Table 5 focuses on the particular read-across problem being addressed. The second to fourth 685 
items address the in vivo data relevant to the read-across. Items five and six relate to the 686 
mechanistically-related in chemico, in vitro and “new methods” data. Item seven addresses the 687 
overall WoE. While a ranking (i.e., low medium or high) is assigned to each item, the comment 688 
section is considered to be more significant and hence of greater value. The overall ranking (low, 689 
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moderate, high) and a summary of the uncertainty associated with the definition of the similarity 690 
of analogues or category members, as reported at the end of the relevant tables, is presented in a 691 
text box in Appendix B. 692 
 693 
5. Workflow for Reporting a Read-Across Prediction 694 
Existing workflows for reporting read-across predictions vary in detail, however the general 695 
purpose is to: 1) describe the similarity rationale of the read-across in a transparent manner, 2) 696 
document the logic and data leading to the read-across prediction so it can be recreated, 3) 697 
describe and address the uncertainties, and 4) clarify the roles of any endpoint specific and/or 698 
endpoint non-specific factors affecting the assessment. 699 
In order to assist with developing a workflow for reporting, the combined process of chemical 700 
category formation and toxicological read-across prediction can be sub-divided into distinct and 701 
definable activities. Cronin (2013a) identified six such procedures associated with development 702 
of a read-across prediction including: 1) the identification of the effect and/or endpoint to be 703 
predicted by read-across and the ‘‘target’’ chemical(s), 2) the identification the source 704 
chemical(s) and other chemicals “similar” to the target, 3) obtaining toxicity data for the 705 
category members identified in 1 and 2, 4) definition of the chemical category, 5) making the 706 
prediction of toxicity by read-across, and 6) fully documenting the prediction. 707 
More recently, the OECD has provided reporting formats for analogue and chemical category 708 
approaches (OECD, 2014a). The documentation of read-across predictions, which are largely 709 
based on process of using the OECD QSAR Toolbox, includes a number of steps: 710 
1) Formulate the problem (i.e., understanding assessment strategy and identify the critical data 711 
needs). 712 
2) Curate chemical structure of the target compound(s) and other category members. 713 
3) Profile the target compound(s) and other category members. 714 
4) Develop the similarity rationale for the read-across prediction. 715 
5) Establish the category selection criteria and search for potential source analogues or 716 
category members. 717 
6) Gather data for the category members and construction of data matrix. 718 
7) Assessing the adequacy and uncertainty associated with the read-across. 719 
8) Applying read-across to fill the data gap. 720 
9) Document the analogue/category and read-across prediction. 721 
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A workflow proposed for reporting a read-across prediction is presented in Appendix C. This 722 
builds on the earlier efforts and reflects the essential points described in this paper to address 723 
similarity, the data and to justify the validity of the prediction. 724 
 725 
6. Discussion 726 
A significant proportion of REACH registration dossiers include a read-across prediction 727 
intended to fill information requirements for higher-tier toxicological studies. In fact, 75% of 728 
registration dossiers include read-across or categorisation reasoning (ECHA 2014) by the 729 
registrant. 730 
Improvements in methodology to perform and report read-across prediction require an 731 
understanding of the process, specifically around the concept of similarity with regard to two or 732 
more chemicals. Berggren et al. (2015) noted that in considering chemical similarities there are 733 
different aspects that must be assessed to make the read-across prediction scientifically justified. 734 
These similarities include aspects of chemical stability, the possible formation of toxic 735 
metabolites, different active functional groups that might lead to similar or dissimilar behaviours, 736 
possible routes of exposure and concentrations at the target tissue, biotransformation (prior to 737 
reaching, or at, the target organ), or observable trends with or without a mechanistic explanation. 738 
To improve and standardise the development and reporting of a read-across prediction, it is, 739 
therefore, useful to identify different scenarios by which a read-across prediction may develop. 740 
While this is possible to do in several ways, the toxicokinetic fate of the substance, such as 741 
whether the compound itself would be available in the target organ or whether it would be its 742 
metabolites or reaction products leading to adverse effect, is a critical factor, especially for 743 
chronic health effects (Berggren et al., 2015). In addition, Berggren et al. (2015) noted that the 744 
toxicodynamic behaviour of the substance and compared similarities of chemicals based on their 745 
assumed mechanism of action, including lack of biological activity, is critical to establish a read-746 
across justification. 747 
Category-based read-across adaptations begin with the definition of a chemical category (i.e., 748 
establishment of the category’s applicability domain). This definition is assumed to be related to 749 
the toxicological property to be read across, which results from a trend observed when the 750 
property to be read across is plotted against another property that is known for all members of 751 
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the category (i.e., an indication of toxicological relevance). Read-across to a target substance is 752 
deemed possible when the target substance is an unambiguous member of the category and there 753 
are one or more measured property(ies) to be read across for other members of the category. 754 
Therefore, a category-approach read-across is based on grouping and may rely on one or more 755 
observed trends. Category-approach read-across also covers cases where substances belonging to 756 
a well-defined category all show the same type and value for the toxicological property to be 757 
read across or do not show an effect at all (i.e., a ‘low-toxicity’  read-across case). 758 
While there is no consensus, there appear to be four most likely scenarios where chemical 759 
category formation and subsequent read-across may be used to fill a data gap, especially for 760 
repeated dose toxicity. Scenarios for read-across in general are described in Table 4, more 761 
specific scenarios for chronic endpoints are given in Table 7. 762 
 763 
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 765 
It is important to remember that defining the criteria for category membership for a particular 766 
scenario of chemical category formation and read-across is only the beginning of the exercise. 767 
Improvement in the confidence of a read-across prediction can be made by added value in the 768 
form of increased WoE. This added value may come from suggestions of how targeted testing 769 
and “new-approach” data, especially when applied using the logic of the Safety Evaluation 770 
Ultimately Replacing Animal Testing (SEURAT) conceptual framework (White and Knight, 771 
2013), may be used to improve the read-across justification. The increase in justification will be 772 
especially true if targeted testing focuses on the weak steps of the read-across argument. In other 773 
words, an understanding of how targeted testing may reduce uncertainty is available, for instance 774 
as stated in Table 6. The improvement of the robustness of the read-across predictions, when 775 
further evidence is added can, in principle, be examined by various means before and after the 776 
addition of further evidence. 777 
The intention of this manuscript was to report progress in the development of proposed templates 778 
and workflows for recording and evaluating traditional in vivo toxicology data, as well as 779 
alternative methods (e.g., in chemico, in vitro) data. Additionally, the intent was to suggest 780 
means to standardise the evaluation of similarity and uncertainty so as to enhance the robustness 781 
of the read-across prediction and thereby make it more likely to gain regulatory acceptance.  782 
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Since there are various over-arching scenarios for category formation and read-across, it is 783 
critical to not only state the target chemical and its missing endpoint value but also the 784 
hypothesis and assumptions on which the read-across is based. A category/analogue hypothesis 785 
typically makes references to several similarity rationales which delineate category membership. 786 
For example, for a read-across adaptation of Scenario 3 noted in Table 7 it may be possibly to 787 
report: 788 
 Members of chemical category A are indirect-acting toxicants of n1 to n2 carbon atoms in 789 
size with a molecular scaffolding of B and the primary functional group C. 790 
 Category members elicit a similar chemical mechanism-of-action (e.g., electrophilic 791 
reactivity via mechanism D), where metabolism via pathway E is the primary factor 792 
driving the reactivity leading to oral repeated dose toxicity with symptoms/endpoints F. 793 
 Category members show rapid and complete absorption from the gut, as the parent 794 
compound with first past through oxidative metabolism in the liver to the corresponding 795 
electrophile with mechanism D. Subsequently, the electrophile elicits the in vitro 796 
outcome G at the cellular level leading to the in vivo outcome F. 797 
 Category members have similar volatility, bioavailability and oral uptake. 798 
 Reading repeated dose toxic outcome F for the source chemical X across to the target 799 
chemical Y is supported by information and data on A, B, C, D, E and G. 800 
Along the same theme, assessments of uncertainty may reveal there are no deficiencies in the 801 
quality of the toxicology data to be read across (F), especially as compared to what is expected 802 
from current standard test methods. However, assessment of uncertainty associated with 803 
similarity justification reveals metabolism via pathway E to be the weak step of the read-across 804 
argument. New methods data after target testing may reduce the uncertainty by strengthening this 805 
step in the similarity argument. 806 
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 950 
Table 1. Criteria for Category Membership 951 
 952 
 953 
  954 
1) A description of structural and chemical property similarities and differences 
among the category analogues and how these similarities and differences are 
linked to the read-across hypothesis. 
a. Supported by a data matrix of key structural and chemical properties. 
2) A description of toxicokinetics and/or abiotic transformation similarities and 
differences among the category analogues and how these are linked to the read-
across hypothesis. 
a. Supported by a data matrix of abiotic and biotic modification properties, 
including a summary of metabolic pathways and metabolites. 
3) A description of the similarity and differences in the bioavailability of  the 
chemical analogues and how these are linked to the read-across hypothesis. 
4) A description of biological and toxicological similarities and differences among 
the category analogues and how these are linked to the read-across hypothesis. 
a. Supported by a data matrix of biological and toxicological properties 
including a summary of toxicological trends within the category. 
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Table 2. Similarities for Establishing a Toxicological Read-Across 955 
1) Molecular structure similarity including common chemical class and sub-class(es), 956 
similar molecular scaffold(s), similar numbers of carbon atoms and common 957 
constituents in the form of key substituent(s), structural fragment(s) and extended 958 
structural group(s).  959 
2) Similar physico-chemical and molecular properties, especially those that are linked to 960 
key factors that affect bioavailability toxicity (e.g., volatility, solubility, reactivity, 961 
etc.). 962 
3) Similar toxicokinetics. 963 
4) The same key abiotic transformation process (e.g., hydrolysis, autooxidation). 964 
5) The same key metabolic pathway(s) or pathway inhibition. 965 
6) Biotic and abiotic activation to the same or similar reactive chemical species. 966 
7) Abiotic (e.g. microbial) degradation to the same or similar chemical species. 967 
8) Similar structural alert, or toxicophore, (i.e., structural fragment(s) and extended 968 
structural group(s) experimentally demonstrated to be associated with a specific toxic 969 
effect that is causally linked with the in vivo endpoint which is read across). 970 
9) Mechanistic plausibility, especially in the form of a common Adverse Outcome 971 
Pathway (AOP) based Molecular Initiating Event (MIE) and /or key intermediate 972 
event(s) causally linked to the in vivo endpoint which is the basis of the read-across. 973 
10) Other data (e.g., in vitro, in chemico, in silico) relevant to the in vivo endpoint which 974 
are the basis of the read-across. 975 
11) Similarity in in vivo toxicological responses within the category 976 
 977 
  978 
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Table 3. Criteria to Establish Similarities for a Toxicological Read-Across 979 
 980 
 981 
  982 
 What are the chemical identifiers and structure of the target substance(s) and the 
source analogue(s)? (see Appendix A, Table A.1) 
 Define the similarity in the physico-chemical and molecular properties of the target 
substance(s) and the source analogue(s). (see Appendix A, Table A.2) 
 Define the similarity of the key substituents, functional group(s) or extended 
fragment, generic class of chemicals and sub-class of the target of the target 
substance(s) and source analogue(s) have? (see Appendix A, Table A.3) 
 Identify any structural differences between the target substance and source 
analogue(s) 
 Establish how structural differences may affect toxicity (or otherwise) through 
similarities, for instance, in in vivo data 
 Define the similarity in abotic transformations and/or toxicokinetics between the 
target substance and source analogue(s) (see Appendix A, Table A.4) 
 Define the similarity in potential metabolic products between the target substance and 
source analogue(s) (see Appendix A, Table A.5) 
 Define the similarity in toxicophores or structural alerts for causally-linked 
toxicological endpoints between the target substance and source analogue(s) (see 
Appendix A, Table A.6) 
 Identify whether the target substance(s) and source analogue(s) have the 
same mechanistical plausibility  and can be linked mechanistically to the 
same AOP, MIE or KEs (see Appendix A, Table A.7) 
 Identify if the target substance(s) and source analogue(s) are linked by 
other toxicologically relevant data (see Appendix A, Table A.8) 
38 
 
Table 4.  Summary of the Main Types of Read-Across Scenario 983 
1. Chemical similarity of compounds that do not require (or do not undergo) 
metabolism to exert a potential adverse human health effect (i.e., direct-acting 
toxicants with a similar mode of toxic action) 
 
2. Chemical similarity involving metabolism and resulting in exposure to the 
same/similar toxicant (i.e., indirect-acting toxicants with a similar mode of toxic 
action based on metabolites with the same mechanism of action) 
 
3. Chemical similarity of compounds with low general or no toxicity (i.e., toxicants 
with no obvious reactive or specific mode of action) 
 
4. Distinguishing chemicals in a structurally similar category with variable toxicities 
based on Mode of Action hypothesis (i.e., toxicants with high structural similarity but 
markedly different potency and/or phenotypic profiles) 
         afrom Schultz (2014) 984 
  985 
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Table 5.  Proposed Factors Affecting Uncertainty Associated with the Mechanistic Relevance and 986 
Completeness of the Read-Across 987 
1) The problem and premise of the read-across. What is the level of complexity of the 
read across endpoint? What is the purpose of the exercise? What is the over-arching 
premise and scenario of the exercise? 
2) Number of source chemicals and their relative applicability domain(s); is it an 
analogue-or category-based read-across?  
3) Absence/presence of toxicity and relevant mechanisms e.g. whether mechanisms can 
be defined for non / low toxicity compounds.  
4) Quality of the in vivo apical endpoint data read across to include technical issues 
related to the performance (e.g., reliability accuracy, precision, repeatability and 
reproducibility of the manner in which apical in vivo data are generated). Is the data 
to be read across sufficient to meet the purpose of the exercise? 
5) Consistency in the severity of the apical in vivo hazard. Is the potency of the hazard 
consistent among the source chemicals? 
6) Robustness of the (in chemico, in vitro and/or other) data sets. How extensive are the 
relevant events empirically measured or modelled? What is the performance (e.g. in 
terms of reliability and reproducibility) of methodology for establishing these data? 
7) Concordance of the in chemico, in vitro and/or other data with regard to the 
intermediate and apical effects and potency data. What is the temporal and dose-
response relationship between mechanistically-relevant endpoints? 
8) The overall Weight-of-Evidence (WoE) supporting the prediction. How many and 
how large are the mechanistically-related data gaps? 
 988 
  989 
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Table 6. Proposed key similarities relating to toxicological read-across and criteria for assessing 990 
uncertainty (adapted from considerations in Blackburn and Stuard, 2014). 991 
 Low 
uncertainty 
Low-to-Moderate 
uncertainty 
Moderate 
uncertainty 
High 
uncertainty 
Core structural 
similarity i.e., 
functional groups, 
extended 
fragments 
(especially those 
associated with 
chemical reactivity 
or its 
modification) 
Highly similar Highly similar Similar Differences in 
core structure 
and functional 
groups 
Physico-chemical 
and molecular 
properties 
Highly similar Similar, having a 
consistent trend 
within values 
Minor 
differences in 
values 
Major 
differences in 
values 
Abiotic 
transformation 
and/or 
toxicokinetics, 
especially 
metabolism e.g., 
leading to a 
common 
metabolite 
Evidence 
demonstrating 
comparability in 
abiotic 
transformation 
and/or 
toxicokinetics  and 
the same 
metabolites, 
similar 
bioavailability 
Evidence 
demonstrating 
comparability in 
abiotic 
transformation 
and/or 
toxicokinetics 
and the same 
metabolites, 
similar 
bioavailability 
 
No evidence that 
abiotic 
transformation 
and/or 
toxicokinetics, 
especially 
metabolism are 
dissimilar 
Differences in 
abiotic 
transformation 
and/or 
toxicokinetics, 
especially in 
metabolism  
Mechanism of 
action and 
toxicological 
properties 
Evidence 
demonstrating 
comparability in 
mechanism 
supported by an 
AOP 
Evidence 
demonstrating 
comparability in 
mechanism, 
possibly 
supported by an 
AOP 
No evidence that 
mechanisms of 
action are 
dissimilar 
Differences in 
mechanism of 
action and/or 
toxicological 
properties 
 992 
  993 
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 1002 
Table 7.  The Most Likely Scenarios for a Chronic Toxicity Endpoint Read-Across 1003 
 1004 
 1005 
 1006 
 1007 
 1008 
  1009 
1) A ‘low-toxicity’ or negative read-across prediction; the category members 
have structural and chemical similarities, toxicokinetics are simple and based 
on well-documented or easily predicted (from related chemicals) pathways 
that lead to rapid degradation and/or elimination and/or generation of non-
toxic metabolites and there is no obvious chemical reactivity or bioactivity or 
specific mode-of-action (i.e., members elicit generic effects but only at high 
concentrations). 
2) A ‘toxicity’ or positive read-across prediction; the category members are 
direct-acting toxicants (i.e., no transformation or transformation does not drive 
the toxicity) with similar chemical mechanism-of-action and mode-of-toxic 
action (i.e., members elicit specific effects at similar internal concentrations or 
according to an established structural-related trend) leading to the same read 
across effect. 
3) A ‘toxicity’ or positive read-across prediction; the category members are 
indirect-acting toxicants (i.e., transformation is the driver of toxicity), where 
the definitive toxicants has the same chemical mechanism-of-action and elicits 
the same mode-of-toxic action leading to the same read across effect. 
4) A “toxicity’ or positive read-across prediction; the category members are 
structurally and chemically highly similar and initially considered similar in 
bioactivity. Subsequently, new methods data reveal dissimilarity in bioactivity, 
often due to the inhibition of a degradative metabolic pathway. Thus, to obtain 
the appropriate read across endpoint effect (e.g., target organ and disease) 
requires sub-categorisation. 
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Appendix A: Template for Reporting Data for Assessing Similarity of Analogues and 1010 
Category Members for Read-Across 1011 
In Table A.1, the substance identification information, 2D structure and molecular formula data 1012 
for the target substance(s) and proposed source analogue(s) are presented for comparison. The 1013 
purpose of this information is to provide, in a transparent manner, a preliminary basis for 1014 
assessing similarity. 1015 
Table A.1: Comparison of Substance Identification, Structure and Chemical Classifications 1016 
 Target Substance Analogue 1 Analogue n 
Name    
CAS No:    
SMILES    
2D Structure    
Molecular Formula:    
 1017 
In Table A.2, selected physico-chemical and molecular property data for the target substance(s) 1018 
and proposed source analogue(s) are presented for comparison. The purpose of this information 1019 
is to provide, in a transparent manner, the chemical property basis for assessing similarity. These 1020 
data may assist in defining the boundaries of the applicability domain of the category, especially 1021 
in regards to in vivo (bioavilability) and in vitro (solubility) toxicity. 1022 
Table A.2: Comparison of Physico-Chemical and Molecular Properties1 1023 
 Target Substance Analogue 1 Analogue n 
Name    
Molecular Weight:    
Log Kow    
Vapor Pressure    
Density    
Melting Point    
Water Solubility    
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 Target Substance Analogue 1 Analogue n 
Boiling Point    
pKa    
1Value typically derived from EPISuite v4.0; 2value for OECD QSAR Toolbox v3.3 1024 
 1025 
In Table A.3, substituents, functional groups and extended structural fragments as well as 1026 
chemical class data for the target substance(s) and proposed source analogue(s) are presented for 1027 
comparison. The purpose of this information is to provide, in a transparent manner, the chemical 1028 
structure sub-fragments and chemical class data for assessing similarity. These data may assist in 1029 
defining the boundaries of the applicability domain of the category. 1030 
Table A.3: Comparison of Substituents, Functional Groups, and Extended Structural 1031 
Fragments 1032 
 Target Substance Analogue 1 Analogue 2 
Name    
Key Substituent(s)    
Functional Group(s)    
Extended Fragment(s)    
Chemical Class:    
Chemical Sub-Class:    
Chemical Sub-Class:    
 1033 
In Table A,4, Transformation information and data for the target substance(s) and proposed 1034 
source analogue(s) are presented for comparison. The purpose of this information is to provide, 1035 
in a transparent manner, assessing similarity in abiotic transformation and/or similarity in the 1036 
absorption, distribution, metabolism and elimination information. 1037 
Table A.4: Comparison of Abiotic Transformation and Toxicokinetics 1038 
 Target Substance Analogue 1 Analogue 2 
Name    
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 Target Substance Analogue 1 Analogue 2 
Abiotic Transformation    
Toxicokinetics    
 1039 
In Table A.5, the predictions of potential metabolites derived from in silico tools data for the 1040 
target substance(s) and proposed source analogue(s) are presented for comparison. A number of 1041 
software platforms provide in silico predictions of metabolism. These are typically based on 1042 
simulations run on the parent compound and initial metabolites using well-studied reactions, 1043 
such as oxidation. Files with name and structure of metabolites should be included for the sake 1044 
of transparency. 1045 
Table A.5: Comparison of Potential Metabolic Products 1046 
 Target Substance Analogue 1 Analogue 2 
Name    
Liver metabolism 
simulator 
Toolbox v3.3 
   
Other software e.g. 
MetaPrint2D-React 
software 
   
Further software for 
prediction of metabolites 
   
 1047 
In Table A.6, any toxicophore (i.e., toxic endpoint- specific structural alerts) data for the target 1048 
substance(s) and proposed source analogue(s) are presented for comparison. A number of 1049 
software platforms provide in silico predictions based on the presence of toxicophores (e.g., 1050 
OECD QSAR Toolbox, Derek Nexus, MCASE (Computer Automated Structure Evaluation)). 1051 
The purpose of this information is to provide, in a transparent manner, any chemical structure 1052 
sub-fragments linked to any relevant biological endpoint for assessing similarity. 1053 
Table A.6: Comparison Toxicophores 1054 
 Target Substance Analogue 1 Analogue 2 
Name    
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 Target Substance Analogue 1 Analogue 2 
Toxicophores    
 1055 
In Table A.7, any mechanistic plausibility data including AOP-related, MIE, KEs, KERs or other 1056 
mechanistically-relevant endpoints for the target substance(s) and proposed source analogue(s) 1057 
are presented for comparison. With few exceptions (e.g., skin sensitisation), there are currently a 1058 
limited number of endpoints for which AOPs, MIEs and KEs test methods and data have been 1059 
formally developed and causally-linked, especially in the form of a KER. However, in the future, 1060 
these pieces of information will become more and more available. 1061 
Table A.7: Comparison of Mechanistic Plausibility and AOP-Related Event Data 1062 
  Target Substance Analogue 1 Analogue 2 
Name    
Mechanistic Plausibility    
Adverse Outcome Pathway or 
Mode of Toxic Action: 
   
Molecular Initiating Event:    
Key Event 1 etc.:     
Key Event Relationship 1 etc.:    
Other Mechanistically-Relevant 
Events 
   
 1063 
In Table A.8, any other toxicologically relevant data for the target substance(s) and proposed 1064 
source analogue(s) are presented for comparison. In some cases, there is relevant data from other 1065 
sources (e.g., alternative species) which can assist in establishing mechanistic similarity. 1066 
Table A.8: Comparison of Other Toxicologically Relevant In Vivo, In Vitro and Ex Vivo 1067 
Data 1068 
 Target Substance Analogue 1 Analogue 2 
Name    
Endpoint:    
Endpoint:    
 1069 
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Appendix B: Template for Assessing Uncertainty for Read-Across 1070 
Table B.1. Data Uncertainty and Weight-of-Evidence Associated with the Fundamentals of 1071 
Chemical, Transformation/Toxicokinetic and Toxicological Similarity 1072 
Similarity 
Parameter 
Data 
Uncertainty a 
(empirical, modelled) 
(low, medium, high) 
Strength of 
Evidence b 
(low, medium, high) 
Comment 
Substance 
Identification, 
Structure and 
Chemical 
Classifications 
  Example: All category members have CAS numbers, similar 
2D structure and belong to the same chemical class/subclass. 
    
Physio-Chemical 
& Molecular 
Properties 
Empirical: 
 
Modelled: 
 Example: All category members are appropriately similar 
with respect to key physicochemical and molecular 
properties. There is a high degree of consistency between 
measured and model estimated values. 
    
Substituents, 
Functional 
Groups, & 
Extended 
Structural 
Fragments 
  Example: Substituents, functional groups and extended 
structural fragments are consistent across all category 
members. 
    
Transformation/
Toxicokinetics 
and Metabolic 
Similarity 
Empirical:  
   In vivo: 
   In vitro: 
 
Simulated: 
 Example: Based on in vivo and in vitro data for multiple 
category members, there is evidence for similar toxicokinetics 
and metabolic pathways. Comparison of results from 
empirical studies and model predictions indicate similar 
metabolism among all category members. 
    
Potential 
Metabolic 
Products 
  Example: Based on in silico metabolic simulations, potential 
metabolic products are similar among all category members. 
    
Toxicophores 
/Mechanistic 
alerts 
  Example: Based on in silico profilers, all category members 
contain the same toxicophores. 
    
Mechanistic 
plausibility and 
AOP-Related 
Events 
  Example: Although no AOP is currently available for the 
hypothesised toxicity pathway, many category members have 
been tested for what is generally accepted as a 
mechanistically-relevant event leading to the in vivo apical 
outcome of interest (a citation could be provided). 
    
other relevant, in 
vivo, in vitro and 
ex vivo 
endpoints 
  Example: Although not part of the hypothesised toxicity 
pathway, many category members have been tested for rodent 
acute oral toxicity and there is general agreement among the 
reported LC50 values. 
 
Overall uncertainty in similarity of category members: (Low, Moderate, High) 
 
Summary: Key features of chemistry are similar within the category.  Key features of transformation toxicokinetics and 
metabolism are common within the category.  Category members are considered mechanistically similar. Category 
members exhibit a similar toxicological profile with respect to in vivo toxicity. 
a Uncertainty associated with underlying information/data used in the exercise 1073 
b Consistency within the information/data used to support the similarity rational and prediction  1074 
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Table B.2. Template for Assessing Uncertainty Associated with Mechanistic Relevance and 1075 
Completeness of the Read-Across 1076 
Factor Uncertainty 
(low, medium, high) 
Comment 
The problem and 
premise of the read-
across 
 Example: The endpoint to be read across, developmental 
toxicity, for the category of branched carboxylic acids is 
well-studied and well-understood, The scenario of the read-
across hinges on the inhibition of beta-oxidation of the acid 
and the subsequent build up of acid in the embryo leading to 
histone deacetylase inhibitors, increased cell adhesion and 
concomitant reduced cell motility, prevention of convergent 
extension during ontogenetic development. 
In vivo data read 
across 
  
Number of analogues in 
the source set 
 Example: There are 3 suitable category members with in 
vivo apical endpoint data usable for read-across. 
   
Quality of the in vivo 
apical endpoint data 
read across 
 Example: High quality empirical data from standard test 
guidelines for the stated regulatory endpoint exists for 1 
category member. Similar non-standard test data of lower 
quality exists for 2 other category members. All these data 
are consistent in regards to qualitative description of effects 
and, where available, similar in quantification. 
   
Severity of the apical in 
vivo hazard 
 Example: Potency data for the in vivo apical endpoint (25 
mg/kg/day) is limited to a single source substance. 
Evidence to biological 
argument for RA 
  
Robustness of analogue 
data set 
 Example: The available data from in silico, in chemico and 
in vitro studies for the category members were judged to be 
reliable and conducted under the appropriate conditions. 
   
Concordance with 
regard to the 
intermediate and apical 
effects and potency 
data 
 Example: There is good agreement between the sequences 
of biochemical and physiological events leading to the in 
vivo apical outcome. There is consistency and high 
specificity for the association between the toxicophore and 
the structural domain of the category. There is general 
agreement among the dose-response relationships of the 
tested category members for mechanistically-relevant 
event(s) which may be assessed in vitro. 
   
Weight of Evidence  Example: Overall the available information is generally 
consistent with the stated hypothesis. The sharp structural 
limitations of the category and narrow range of chemical 
properties strengthens the WoE. While the toxicokinetics 
data is limited, the lack of inconsistencies adds to the WoE. 
While the source substances data is limited, the fact that 
there is consistent relevant in vitro data for 50% of the 
category members, including the target chemical, strengthens 
the WoE. 
   
Overall uncertainty of the read across: (Low, Medium, High) 
 
Uncertainty associated with the read-across is judged to be low. 
 1077 
 1078 
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Summary of Uncertainty 1079 
Example: Overall, the uncertainty in similarity of the analogues or category member is low. The 1080 
key features (i.e., A and B) relevant for toxicity are common within the category. There are only 1081 
minor differences among the analogues or category members with respect to physicochemical 1082 
properties. Analogues or category members are considered chemically similar (i.e., C). 1083 
Analogues or category members are judged to follow the same or similar metabolism. Analogues 1084 
or category members exhibit a similar toxicological profile (i.e., D and E) with respect to the 1085 
endpoint in question. It is concluded that the structural difference between analogues, 1086 
hydrocarbon chain length, has no significant impact on the toxicity being read across. 1087 
 1088 
  1089 
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Appendix C. Work Flow for Reporting a Read-Across Prediction 1090 
 1091 
1. Statement target substance(s) and the regulatory endpoint(s) that is to be read across. 1092 
The specific data gap to be filled by the prediction needs to be clearly defined by listing the 1093 
chemical(s) and toxicity endpoint(s) (i.e., property(s)) for which the read-across prediction is 1094 
proposed. 1095 
2. Description of the analogues or members of the category. 1096 
2.1. Premise 1097 
A premise for the basis of the analogue or category needs to be presented. This hypothesis 1098 
should note the relational chemical, toxicokinetic and biological/toxicological features (i.e., 1099 
structural similarities) which are deemed to be collectively relevant to the endpoint(s) being read 1100 
across and common to target and source substance or all members of the category. 1101 
2.2. Justification 1102 
The analogue or category should be justified based on available experimental data, especially for 1103 
the source substance(s). This is a description of the experimental toxicological data for the 1104 
analogues or category members, presented in a narrative fashion. Typically, this justification will 1105 
include endpoint-related mammalian toxicity data via appropriate exposure schemes, 1106 
toxicokinetic and transformation information, as well as relevant in vitro data and structure-1107 
activity relationships. These data should demonstrate that the quality and quantity of in vivo data 1108 
to be read across is sufficient to proceed with the exercise. Moreover, these data should be 1109 
summarised to show the robustness of the read-across and include any indication of data trend(s) 1110 
within the category for the different endpoints noted. 1111 
2.3. Applicability domain 1112 
In a category approach, the applicability domain of the category is described by inclusion and/or 1113 
exclusion rules that identify the extent of values for category members within which reliable 1114 
predictions can be made. Examples of this are the range of 1-octanol/ water partition coefficients 1115 
values, functional groups or carbon chain lengths within which the category is appropriate. 1116 
2.4. Analogues or category members 1117 
Analogues or all members of the category, including target(s) and source substance(s), 1118 
incorporated in the read-across exercise need to be described in a comprehensive fashion that 1119 
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takes into account unique substance identifiers such as, names, chemical structures and CAS 1120 
numbers. 1121 
2.5. Purity/impurities 1122 
A purity/impurity profile for each analogue listed in 2.4 needs to be cataloged. The potential 1123 
impact of impurities on the endpoint(s) being considered in the adaptation should be identified. 1124 
3. Data matrices for assessing similarity 1125 
Appendix A presented the template for assessing similarity. These data matrices are the central 1126 
part of the workflow. They are likely to be the first items examined in any assessed. Data should 1127 
be reported clearly, logically and unambiguously. The key study results should be noted and 1128 
referenced. The distinction between experimentally measured and model-derived data should be 1129 
noted. 1130 
4. Statement of uncertainty 1131 
Appendix B presented the template for assessing uncertainty. This section concludes with a 1132 
narrative summary of the uncertainty. Particular consideration needs to be given to pointing out 1133 
what are considered to be the weak steps of the read-across argument; why they are considered 1134 
weak and how they impact the uncertainty of the read-across prediction. 1135 
5. Statement of the conclusions 1136 
Lastly, an overall concluding statement is made with regard to the category and the read across 1137 
prediction relevant to the regulatory decision (e.g., hazard identification, classification and 1138 
labelling, risk assessment, etc.) being considered. This should include making the prediction of 1139 
toxicity by read-across and fully documenting the prediction to include clarifying the roles of any 1140 
endpoint specific and/or endpoint non-specific factors affecting the prediction. 1141 
